MARKET

ONCY

ONCY

Oncolytics Biotech Inc
NASDAQ
0.8400
-0.0610
-6.77%
After Hours: 0.8900 +0.05 +5.95% 19:59 03/27 EDT
OPEN
0.9000
PREV CLOSE
0.9010
HIGH
0.9216
LOW
0.8195
VOLUME
1.70M
TURNOVER
--
52 WEEK HIGH
1.510
52 WEEK LOW
0.3258
MARKET CAP
90.39M
P/E (TTM)
-2.9808
1D
5D
1M
3M
1Y
5Y
1D
Geron appoints Patricia S. Andrews and Constantine Chinoporos to board of directors
Reuters · 3d ago
Weekly Report: what happened at ONCY last week (0316-0320)?
Weekly Report · 6d ago
Oncolytics Biotech Shifts Corporate Domicile to British Columbia
TipRanks · 03/20 21:00
Oncolytics Biotech Showcases Pelareorep as Immune-Priming Backbone With New AACR 2026 Data
TipRanks · 03/19 18:05
Oncolytics Highlights New Pelareorep Data in Cancer Immunotherapy
TipRanks · 03/19 13:29
Oncolytics to present new data on Pelareorep at AACR 2026
TipRanks · 03/19 13:16
Oncolytics Biotech to present pelareorep data at AACR 2026
Reuters · 03/19 13:02
Stocks in play: Oncolytics Biotech Inc
Barchart · 03/19 09:02
More
About ONCY
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The Company is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

Webull offers Oncolytics Biotech Inc stock information, including NASDAQ: ONCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ONCY stock methods without spending real money on the virtual paper trading platform.